{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    41,
    43,
    44,
    45,
    47,
    48,
    49,
    50,
    51,
    62,
    63
  ],
  "modelUsed": "gemini-2.5-pro",
  "confidence": 0.7941489361702128,
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "Screening visit",
        "anchorType": "Screening",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Screening\nPeriod",
        "confidence": 0.7
      },
      {
        "id": "anchor_2",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Informed Consent",
        "confidence": 0.75
      },
      {
        "id": "anchor_3",
        "definition": "Procedure",
        "anchorType": "Custom",
        "timelineId": null,
        "dayValue": 1,
        "sourceText": "Procedure",
        "confidence": 0.85
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "confidence": 0.8,
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "confidence": 0.8,
        "sourceText": "tid"
      },
      {
        "id": "rep_interval_5",
        "type": "Interval",
        "confidence": 0.9,
        "interval": "PT15M",
        "minObservations": 5,
        "sourceText": "Predose, 15, 30, \n60, 120, 240 min"
      },
      {
        "id": "rep_interval_9",
        "type": "Interval",
        "confidence": 0.9,
        "interval": "PT5M",
        "minObservations": 12,
        "sourceText": "Predose, 5, 10, 15, \n20, 25, 30, 40, 50, \n60, 90, 120, 240 \nmin"
      },
      {
        "id": "rep_interval_13",
        "type": "Interval",
        "confidence": 0.9,
        "interval": "PT15M",
        "minObservations": 4,
        "sourceText": "Predose, 15, 30, \n60, 120 min"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "confidence": 0.9,
        "startOffset": "P28D",
        "endOffset": "P2D",
        "sourceText": "Days -28\nto -2"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "confidence": 0.85,
        "sourceText": "washout period"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "confidence": 0.85,
        "sourceText": "Screening\nPeriod"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "confidence": 0.85,
        "sourceText": "screening period"
      },
      {
        "id": "rep_window_12",
        "type": "Continuous",
        "confidence": 0.85,
        "sourceText": "washout \nperiod"
      },
      {
        "id": "rep_window_13",
        "type": "Continuous",
        "confidence": 0.85,
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_17",
        "type": "Continuous",
        "confidence": 0.85,
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "confidence": 0.8,
        "sourceText": "30 days after"
      },
      {
        "id": "rep_window_19",
        "type": "Continuous",
        "confidence": 0.8,
        "sourceText": "2 days \nafter"
      },
      {
        "id": "rep_window_23",
        "type": "Continuous",
        "confidence": 0.8,
        "sourceText": "6 hours after"
      },
      {
        "id": "rep_window_24",
        "type": "Continuous",
        "confidence": 0.8,
        "sourceText": "4 hours after"
      }
    ],
    "samplingConstraints": [
      {
        "id": "pk_sampling_1",
        "activityId": "PK_Blood_Sampling",
        "minPerWindow": 4,
        "windowDuration": "PT3H",
        "timepoints": [
          "15 minutes",
          "30 minutes",
          "60 minutes",
          "120 minutes"
        ],
        "sourceText": "Predose, 15, 30, \n60, 120 min"
      }
    ],
    "traversalConstraints": [
      {
        "id": "traversal_crossover_1",
        "requiredSequence": [
          "SCREENING",
          "PERIOD_1",
          "PERIOD_2",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "sourceText": "crossover study",
        "confidence": 0.95
      },
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "BASELINE",
          "TREATMENT",
          "WASHOUT",
          "FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Day 1",
          "End of Study"
        ],
        "confidence": 0.75
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "confidence": 0.9,
        "rationale": "EPISODE signals: 8; SINGLE signals: 4"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Window",
        "confidence": 0.9,
        "rationale": "WINDOW signals: 3; EPISODE signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "confidence": 0.9,
        "rationale": "WINDOW signals: 1; EPISODE signals: 2; SINGLE signals: 2; RECURRING signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "confidence": 0.5,
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Episode",
        "confidence": 0.9,
        "rationale": "EPISODE signals: 5; SINGLE signals: 2"
      },
      {
        "activityId": "Concomitant\nMedications",
        "executionType": "Single",
        "confidence": 0.85,
        "rationale": "WINDOW signals: 2; EPISODE signals: 1; SINGLE signals: 4"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Window",
        "confidence": 0.9,
        "rationale": "WINDOW signals: 1; SINGLE signals: 1"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "confidence": 0.9,
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Episode",
        "confidence": 0.9,
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Glucose Measurement",
        "executionType": "Episode",
        "confidence": 0.9,
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Insulin Infusion",
        "executionType": "Single",
        "confidence": 0.75,
        "rationale": "WINDOW signals: 3; SINGLE signals: 6"
      },
      {
        "activityId": "Dosing",
        "executionType": "Episode",
        "confidence": 0.85,
        "rationale": "EPISODE signals: 10; SINGLE signals: 1"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "confidence": 0.5,
        "rationale": "No strong signals detected"
      }
    ],
    "crossoverDesign": {
      "id": "crossover_1",
      "isCrossover": true,
      "numPeriods": 2,
      "numSequences": 2,
      "periods": [
        "Period 1",
        "Period 2"
      ],
      "sequences": [
        "AB",
        "BA"
      ],
      "washoutRequired": false,
      "sourceText": "crossover study",
      "confidence": 0.95
    },
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "frequency_daily",
        "text": "multiple daily injection of long-acting insulin analog",
        "footnoteId": "[A]",
        "sourceText": "multiple daily injection of long-acting insulin analog",
        "confidence": 0.9
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_before",
        "text": "women of childbearing potential participating must test negative for \npregnancy prior to initiation of treatment as indicated by a negative serum \npregnancy test at the screening visit followed by a negative urine \npregnancy test within",
        "footnoteId": "[A]",
        "sourceText": "women of childbearing potential participating must test negative for \npregnancy prior to initiation ",
        "confidence": 0.8
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "either one highly effective method of contraception or a combination \nof",
        "footnoteId": "[B]",
        "sourceText": "either one highly effective method of contraception or a combination \nof",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_4",
        "conditionType": "general",
        "text": "postmenopausal, defined as either:",
        "footnoteId": "[B]",
        "sourceText": "postmenopausal, defined as either:",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "cessation of menses for at least",
        "footnoteId": "[a]",
        "sourceText": "cessation of menses for at least",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "if warranted and agreed upon between both the investigator and sponsor",
        "footnoteId": "(s)",
        "sourceText": "if warranted and agreed upon between both the investigator and sponsor",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_7",
        "conditionType": "general",
        "text": "Predose time point will be\nbetween insulin infusion \nstop and study treatment",
        "footnoteId": "L.",
        "sourceText": "Predose time point will be\nbetween insulin infusion \nstop and study treatment",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_8",
        "conditionType": "general",
        "text": "a\nSamples for immunogenicity, should be collected every",
        "footnoteId": "s.",
        "sourceText": "a\nSamples for immunogenicity, should be collected every",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_9",
        "conditionType": "timing_after",
        "text": "Note:  if multiple procedures take place at the same time point, the following order of the procedure should be used:  ECG, vital signs, and venipuncture",
        "footnoteId": "r.",
        "sourceText": "Note:  if multiple procedures take place at the same time point, the following order of the procedur",
        "confidence": 0.8
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "The nature of any conditions present at the time of the physical examination and any preexisting \nconditions will be documented",
        "footnoteId": "G.",
        "sourceText": "The nature of any conditions present at the time of the physical examination and any preexisting \nco",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_11",
        "conditionType": "general",
        "text": "Patients who are not enrolled within",
        "footnoteId": "t.",
        "sourceText": "Patients who are not enrolled within",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_12",
        "conditionType": "general",
        "text": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \nprotocol waivers or exemptions, are not permitted",
        "footnoteId": "y.",
        "sourceText": "Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as \np",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "The patient may \nchoose to use a double barrier method of contraception",
        "footnoteId": "d.",
        "sourceText": "The patient may \nchoose to use a double barrier method of contraception",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_14",
        "conditionType": "general",
        "text": "Thus, each barrier method must include use of a \nspermicide",
        "footnoteId": "d.",
        "sourceText": "Thus, each barrier method must include use of a \nspermicide",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_15",
        "conditionType": "general",
        "text": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \nwill be destroyed within",
        "footnoteId": "y.",
        "sourceText": "Unless otherwise stated in subsections below, all samples collected for specified laboratory tests \n",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_16",
        "conditionType": "procedure_conditional",
        "text": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, regulations, or \nlaboratory certification standards",
        "footnoteId": "s.",
        "sourceText": "Certain samples may be \nretained for a longer period, if necessary, to comply with applicable laws, ",
        "confidence": 0.85
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_after",
        "text": "Blood pressure and pulse rate should be measured after at least",
        "footnoteId": "d.",
        "sourceText": "Blood pressure and pulse rate should be measured after at least",
        "confidence": 0.8
      },
      {
        "id": "fn_cond_18",
        "conditionType": "general",
        "text": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \nposture-induced symptoms",
        "footnoteId": "e.",
        "sourceText": "Unscheduled orthostatic vital signs should be assessed, if possible, during any AE of dizziness or \n",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "If the patient feels unable to stand, supine \nvital signs only will be recorded",
        "footnoteId": "s.",
        "sourceText": "If the patient feels unable to stand, supine \nvital signs only will be recorded",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_20",
        "conditionType": "general",
        "text": "Single ECGs will be collected and stored locally at the investigator’s site",
        "footnoteId": "F.",
        "sourceText": "Single ECGs will be collected and stored locally at the investigator’s site",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "The central ECG laboratory will perform a basic quality control check",
        "footnoteId": "y.",
        "sourceText": "The central ECG laboratory will perform a basic quality control check",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further evaluation of machine-read \nmeasurements or to meet regulatory requirements",
        "footnoteId": "e.",
        "sourceText": "At a future time, the stored \nECG data may be overread at the central ECG laboratory for further eva",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_23",
        "conditionType": "general",
        "text": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass spectrometry method",
        "footnoteId": "r.",
        "sourceText": "Concentrations of glucagon will be assayed using a validated liquid chromatography with \ntandem mass",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_24",
        "conditionType": "general",
        "text": "The samples will be stored for up to a maximum of",
        "footnoteId": "s.",
        "sourceText": "The samples will be stored for up to a maximum of",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_25",
        "conditionType": "general",
        "text": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time points to determine \nthe concentrations of glucagon",
        "footnoteId": "n.",
        "sourceText": "To interpret the results of \nimmunogenicity, a venous blood sample may be collected at the same time",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_26",
        "conditionType": "general",
        "text": "A PK sample may be collected at these \nsame time points",
        "footnoteId": "t.",
        "sourceText": "A PK sample may be collected at these \nsame time points",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_27",
        "conditionType": "general",
        "text": "Treatment-emergent antidrug antibodies",
        "footnoteId": "r.",
        "sourceText": "Treatment-emergent antidrug antibodies",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_28",
        "conditionType": "general",
        "text": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
        "footnoteId": "t.",
        "sourceText": "A PK \nsample may be collected at the follow-up immunogenicity assessment",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_29",
        "conditionType": "general",
        "text": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; however, if patients are unwilling or \nunable to return for the visit, this is not considered a protocol violation",
        "footnoteId": "r.",
        "sourceText": "Every attempt should be made to contact \npatients for the follow-up immunogenicity assessment; howev",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_30",
        "conditionType": "general",
        "text": "male patients: agree to use an effective method of contraception for the \nduration of the study and for",
        "footnoteId": "[2]",
        "sourceText": "male patients: agree to use an effective method of contraception for the \nduration of the study and ",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_31",
        "conditionType": "general",
        "text": "female patients:",
        "footnoteId": "[3]",
        "sourceText": "female patients:",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_32",
        "conditionType": "general",
        "text": "Study Population\nEligibility of patients for the study will be based on the results of screening medical history, \nphysical examination, vital signs, clinical laboratory tests, and ECG",
        "footnoteId": "6.",
        "sourceText": "Study Population\nEligibility of patients for the study will be based on the results of screening med",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_33",
        "conditionType": "timing_after",
        "text": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the following criteria at \nscreening and/or enrollment:",
        "footnoteId": "1.",
        "sourceText": "Inclusion Criteria\nPatients are eligible for inclusion in the study only if they meet all of the fol",
        "confidence": 0.8
      },
      {
        "id": "fn_cond_34",
        "conditionType": "general",
        "text": "Study Assessments and Procedures\nSection",
        "footnoteId": "9.",
        "sourceText": "Study Assessments and Procedures\nSection",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_35",
        "conditionType": "general",
        "text": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
        "footnoteId": "1.",
        "sourceText": "Efficacy Assessments\nPlasma glucose levels will be measured as described in Section",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_36",
        "conditionType": "general",
        "text": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving treatment success, defined \nas either an increase in PG to >",
        "footnoteId": "1.",
        "sourceText": "Primary Efficacy Assessments\nThe primary efficacy measure is the proportion of patients achieving tr",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_37",
        "conditionType": "general",
        "text": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynamic",
        "footnoteId": "2.",
        "sourceText": "Secondary Efficacy Assessments\nSecondary efficacy measures will be determined from the pharmacodynam",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_38",
        "conditionType": "general",
        "text": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-reported assessment tool",
        "footnoteId": "3.",
        "sourceText": "Exploratory Efficacy Assessments\nSubjective hypoglycemia symptoms will be assessed using a self-repo",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_39",
        "conditionType": "general",
        "text": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bedside for clinical \nassessments of the patient during the insulin infusion and for the",
        "footnoteId": "1.",
        "sourceText": "Insulin-induced Hypoglycemia\nA study investigator, or qualified designee, must be present at the bed",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_40",
        "conditionType": "general",
        "text": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY",
        "footnoteId": "4.",
        "sourceText": "Treatment of Overdose\nFor the purposes of this study, an overdose of LY",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_41",
        "conditionType": "general",
        "text": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix",
        "footnoteId": "1.",
        "sourceText": "Laboratory Tests\nFor each patient, laboratory tests detailed in Appendix",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_42",
        "conditionType": "general",
        "text": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule of \nActivities",
        "footnoteId": "2.",
        "sourceText": "Vital Signs\nFor each patient, vital sign measurements should be conducted according to the Schedule ",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_43",
        "conditionType": "general",
        "text": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the Schedule of \nActivities",
        "footnoteId": "3.",
        "sourceText": "Electrocardiograms\nFor each patient, single and triplicate ECGs should be collected according to the",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_44",
        "conditionType": "general",
        "text": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facility \ndesignated by the sponsor",
        "footnoteId": "1.",
        "sourceText": "Bioanalysis\nSamples will be analyzed at a laboratory approved by the sponsor and stored at a facilit",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_45",
        "conditionType": "general",
        "text": "Pharmacodynamics\nAt times specified in the Schedule of Activities",
        "footnoteId": "7.",
        "sourceText": "Pharmacodynamics\nAt times specified in the Schedule of Activities",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_46",
        "conditionType": "general",
        "text": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities",
        "footnoteId": "1.",
        "sourceText": "Immunogenicity Assessments\nAt the visits and times specified in the Schedule of Activities",
        "confidence": 0.5
      },
      {
        "id": "fn_cond_47",
        "conditionType": "general",
        "text": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \ndefinition of treatment emergent, then, at the discretion of the sponsor, patients should be called \nback to the site for follow-up immunogenicity assessment",
        "footnoteId": "6.",
        "sourceText": "If the \nimmunogenicity titer at the last scheduled assessment or discontinuation visit meets the \nde",
        "confidence": 0.5
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Exploratory Endpoint 1",
        "endpointType": "Exploratory",
        "confidence": 0.5,
        "inputs": [
          "PG",
          "efficacy outcomes",
          "insulin",
          "CR",
          "glucose",
          "PR",
          "OS",
          "is the"
        ],
        "timeWindow": {
          "reference": "nadir within",
          "duration": "P60D"
        },
        "algorithm": "either an increase in pg to >70 mg/dl or an increase of >20 mg/dl from nadir within \n30 minutes after administration of glucagon",
        "successCriteria": "treatment success, defined \nas either an increase in pg to >70 mg/dl or an increase of >20 mg/dl from nadir within \n30 minutes after administration of glucagon",
        "unit": "mg/dl",
        "sourceText": "--- Page 36 ---\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 35\nLY900018\n9. Study Assessments and Procedures\nSection 2 lists the Schedule of Activities, detailing the study procedures and their "
      },
      {
        "id": "ep_2",
        "name": "is to demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the \nproportion (NIM=10%) of Ja",
        "endpointType": "Primary",
        "confidence": 0.9,
        "inputs": [
          "PG",
          "CR",
          "glucose",
          "treatment success",
          "PR",
          "to raise",
          "OS"
        ],
        "timeWindow": {
          "reference": "pg nadir",
          "duration": "PT30M"
        },
        "algorithm": "either an increase in pg to ≥70 mg/dl or an increase of ≥20 mg/dl from pg nadir \nwithin 30 minutes after receiving study treatment",
        "successCriteria": "either an increase in pg to ≥70 mg/dl or an increase of ≥20 mg/dl from pg nadir \nwithin 30 minutes after receiving study treatment",
        "unit": "mg",
        "sourceText": "primary objective is to demonstrate that 3 mg LY900018 is non-inferior to 1 mg IMG for the \nproportion (NIM=10%) of Japanese patients with T1DM or T2DM who achieve treatment \nsuccess without receiving"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "PG concentrations",
        "variableType": "ChangeFromBaseline",
        "confidence": 0.95,
        "sourceVariables": [
          "AST",
          "glucose",
          "HbA1c",
          "consultation with",
          "ALT",
          "observed medians",
          "standard \ndescriptive",
          "concentrations of",
          "a self",
          "descriptive methodology",
          "creatinine",
          "actual time",
          "clarke hypoglycemia",
          "wilcoxon signed",
          "preferred terms",
          "hemoglobin",
          "standard noncompartmental",
          "nca",
          "baseline"
        ],
        "derivationRule": "the sum of the scores for each question",
        "baselineVisit": "day\n-1",
        "analysisWindow": "day 1",
        "unit": "described",
        "sourceText": "--- Page 19 ---\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 18\nLY900018\nScreening\nPeriod 1\nWash \nout\nPeriod 2\nFollow-up/ED\nAdditional \nFollow-up for \nTE ADAa\nComments\nProcedure\nDays -28\nto -2\nD"
      },
      {
        "id": "dv_2",
        "name": "concentrations of",
        "variableType": "ChangeFromBaseline",
        "confidence": 0.95,
        "sourceVariables": [
          "glucose",
          "change from"
        ],
        "derivationRule": "post_value - baseline_value",
        "sourceText": "\n1.5 hours\n\n\n--- Page 51 ---\nI8R-JE-IGBJ(a) Clinical Pharmacology Protocol\nPage 50\nLY900018\nBGmax\nmaximal plasma glucose concentration\nDurationabove\nduration above normal range\nDurationbelow\nduration "
      },
      {
        "id": "dv_3",
        "name": "may be",
        "variableType": "Custom",
        "confidence": 0.5,
        "sourceVariables": [
          "HbA1c",
          "glucose",
          "AST",
          "wilcoxon signed"
        ],
        "derivationRule": "210 minutes per period/3 = 70 samples per period × 2 periods = 140 samples total",
        "baselineVisit": "screening",
        "unit": "90",
        "sourceText": "\n1.5 hours\nBGmax\nmaximal plasma glucose concentration\nTmax\ntime to maximal concentration\nBaseline PG concentrations will be concentrations from samples obtained immediately prior to \nglucagon dosing ("
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Completed",
        "Discontinued",
        "Withdrawn",
        "Death",
        "LostToFollowUp"
      ],
      "states": [
        "Screening",
        "Enrolled",
        "OnTreatment",
        "FollowUp",
        "Completed",
        "Discontinued",
        "Withdrawn",
        "Death"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Enrolled",
          "trigger": "Progress from Screening to Enrolled"
        },
        {
          "fromState": "Enrolled",
          "toState": "OnTreatment",
          "trigger": "Progress from Enrolled to OnTreatment"
        },
        {
          "fromState": "OnTreatment",
          "toState": "FollowUp",
          "trigger": "Progress from OnTreatment to FollowUp"
        },
        {
          "fromState": "FollowUp",
          "toState": "Completed",
          "trigger": "Progress from FollowUp to Completed"
        },
        {
          "fromState": "OnTreatment",
          "toState": "Discontinued",
          "trigger": "Discontinuation from treatment"
        }
      ],
      "confidence": 0.8
    }
  }
}